Taxol-based eluting stents from theory to human validation: clinical and intravascular ultrasound observations.
Treatment with antiproliferative drugs via coated stents appears to be a promising approach to both mechanically remodel target lesions and biologically reduce neointimal hyperplasia. Drug-eluting stents can maximize local drug effects and minimize the potential for systemic toxic effects. The purpose of this review is to describe the effects of a lipophilic microtubular inhibitor, paclitaxel, a strong antiproliferative agent under clinical investigation, and to define the vascular response to taxol-based eluting stents by intravascular ultrasound.
Sonoda
Shinjo
S
Division of Cardiovascular Medicine, Stanford University Medical Center, California 94305, USA.
Honda
Yasuhiro
Y
Kataoka
Toru
T
Bonneau
Heidi N
HN
Sudhir
Krishnankutty
K
Yock
Paul G
PG
Mintz
Gary S
GS
Fitzgerald
Peter J
PJ
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D019917:Blood Vessel Prosthesis Implantation; D006348:Cardiac Surgical Procedures; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible / Q000494:pharmacology* / Q000627:therapeutic use*; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control; D006801:Humans; D017239:Paclitaxel / Q000494:pharmacology* / Q000627:therapeutic use*; D015203:Reproducibility of Results; D015607:Stents; D018084:Ultrasonography, Interventional
D020533:Angiogenesis Inhibitors; D020099:Coated Materials, Biocompatible; D017239:Paclitaxel